Studies uncovering the cellular mechanisms of adaptation to varying oxygen levels were recognized with the 2019 Nobel Prize in Physiology or Medicine. Here, we focus on the remarkable parallels between the pathways regulating oxygen availability and those driving rare neuroendocrine tumours, phaeochromocytomas and paragangliomas, and discuss the translational implications of this connection.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Increased expression of Nrf2 and elevated glucose uptake in pheochromocytoma and paraganglioma with SDHB gene mutation
BMC Cancer Open Access 18 March 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kaelin, W. G. Jr, Ratcliffe, P. J. & Semenza, G. L. Pathways for oxygen regulation and homeostasis: the 2016 Albert Lasker Basic Medical Research Award. JAMA 316, 1252–1253 (2016).
Dahia, P. L. et al. A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet. 1, 72–80 (2005).
Hammarlund, E. U., von Stedingk, K. & Påhlman, S. Refined control of cell stemness allowed animal evolution in the oxic realm. Nat. Ecol. Evol. 2, 220–228 (2018).
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–74 (2011).
Fishbein, L. et al. Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell 31, 181–193 (2017).
Zhuang, Z. et al. Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N. Engl. J. Med. 367, 922–930 (2012).
Toledo, R. A. New HIF2alpha inhibitors: potential implications as therapeutics for advanced pheochromocytomas and paragangliomas. Endocr. Relat. Cancer 24, C9–C19 (2017).
Saldana, M. J., Salem, L. E. & Travezan, R. High altitude hypoxia and chemodectomas. Hum. Pathol. 4, 251–263 (1973).
Vaidya, A. et al. EPAS1 Mutations and paragangliomas in cyanotic congenital heart disease. N. Engl. J. Med. 378, 1259–1261 (2018).
Courtney, K. D. et al. Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2alpha antagonist in patients with previously treated advanced clear cell renal cell carcinoma. J. Clin. Oncol. 36, 867–874 (2018).
Acknowledgements
P.L.M.D. is the Charles Tucker Hayes Chair in Oncology and is supported by the NIH (GM114102), Alex’s Lemonade Stand Foundation for Childhood Cancer Innovation Award (co-funded by Flashes of Hope and Northwest Mutual) and National Center for Advancing Translational Sciences (UL1 TR002645). R.A.T. holds a Miguel Servet-I research contract by Institute of Health Carlos III (ISCIII) of the Ministry of Economy (CP17/00199) and Competitiveness; is supported by an Olga Torres Foundation emerging researcher grant and by the Swiss Bridge Award for cancer immunotherapy research; and received a research grant from Novartis.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Supplementary information
Rights and permissions
About this article
Cite this article
Dahia, P.L.M., Toledo, R.A. Recognizing hypoxia in phaeochromocytomas and paragangliomas. Nat Rev Endocrinol 16, 191–192 (2020). https://doi.org/10.1038/s41574-020-0324-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41574-020-0324-1